Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
Date:9/9/2008

elopment; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Barbara Lindheim

(800) 987-8256 (212) 918-4650

PEREGRINE PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

JULY 31, APRIL 30,

2008 2008

Unaudited

ASSETS

CURRENT ASSETS:

Cash and cash equivalents $9,963,000 $15,130,000

Trade and other receivables 2,099,000 605,000

Government contract receivables 1,794,000 -

Inventories, net 4,628,000 2,900,000

Prepaid expenses and other current assets 1,198,000 1,208,000


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
2. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
3. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
4. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
5. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
6. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
7. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
8. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
9. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
10. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... BOTHELL, Wash. , Dec. 24, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... announced that it will hold its 2015 Annual Meeting ... Because the expected date for the Annual ...
(Date:12/24/2014)... SoundConnect’s 2015 ... introduce cutting edge communication technology, provide continued ... platform upgrades. This webinar series demonstrates online ... their quest to leverage web conferencing’s most ... SoundConnect’s Marketing Manager, Seanna Baumgartner, “Our webinars ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. ... American Society for Reproductive Medicine (ASRM), a leading professional ... medicine. In his new role as treasurer, Dr. ... and will have a voice in furthering the mission ... ASRM since 1984 when he joined while conducting fellowship ...
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, Inc. ... on gynecologic disease, announced today that investors including ... Birchview Fund LLC and several Vermillion directors have ... shares of Vermillion,s common stock and warrants to ... a private placement.  Under the ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... - Wisconsin manufacturers made $215 million in efficiency ... Wisconsin Manufacturers Extension Partnership (WMEP) during the organization's last ... is a state-supported, non-profit organization providing consulting services to ... was based on a survey of its clients. It ...
... - The Wisconsin Economic Summit served its purpose ... four summits that took place between 2000 and 2003 ... that are shaping the state's growth. But once those ... to do something about them, the Wisconsin Economic Summit ...
... conference on protecting the U.S. food supply from terrorism and ... until spring from its original November dates. , ,The ... 1-3 in downtown Milwaukee, with as many as 1,000 people ... David Duecker, who, with the Wisconsin Procurement Institute, is helping ...
Cached Biology Technology:Manufacturing group says efforts led to big improvements 2Forum builds on the work of the Wisconsin Economic Summit 2Forum builds on the work of the Wisconsin Economic Summit 3
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
(Date:11/21/2014)... 2014 According to a new ... (Video, RFID, Access Control, Intrusion Detection, Parking Management, Under ... Component Service Geography - Global Forecasts to 2020", published ... to be around $25 Billion in 2014 and is ... a CAGR of 8.69%. Browse 116 market ...
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... the most common primary brain tumor, new findings may ... A UCSF-led team of scientists has identified for ... cells underly a type of glioma called oligodendroglioma. ... therapy than other brain tumors such as glioblastoma multiforme. ...
... Aviv ― Environmentalists around the world agree ― plastic bags ... a Tel Aviv University researcher is developing new laboratory methods ... those that biodegrade and are even tougher than those made ... answer to the problem, Prof. Moshe Kol of Tel Aviv ...
... plants to biofuels is that the very same molecules that ... down. Now scientists at the U.S. Department of Energy,s (DOE) ... structural supports - their cell walls - are made, with ... more efficient biofuel production. In a paper to be ...
Cached Biology News:Cell of origin for brain tumors may predict response to therapy 2Cell of origin for brain tumors may predict response to therapy 3The sweetness of biodegradable plastics 2Scientists unravel more details of plant cell-wall construction 2
prototype Nco I...
Request Info...
Agarose for baculovirus plaque assays which allow optimal growth of plated insect cells....
Includes USB cable, custom driver and one roll of thermal paper...
Biology Products: